Vascular disease and risk factors are associated with cognitive decline in the Alzheimer disease spectrum

Alzheimer Disease and Associated Disorders

Volumn 29, Issue 1, 2015, Pages 18-25

  Lorius, Natacha ^a,b   Locascio, Joseph J ^b   Rentz, Dorene M ^a,b   Johnson, Keith A ^a,c   Sperling, Reisa A ^a,b   Viswanathan, Anand ^b   Marshall, Gad A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Departments of Neurology   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer disease; memory; mild cognitive impairment; processing speed; vascular risk factors

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; GLUCOSE; HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYMPTOM; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VERY ELDERLY; WECHSLER INTELLIGENCE SCALE; WHITE MATTER; COGNITION DISORDERS; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGY; RISK FACTOR; VASCULAR DISEASES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS; VASCULAR DISEASES;

EID: 84924243730     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000043     Document Type: Article

References (42)

1. Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord. 2006;20:93-100.
2. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
3. Carter DB. The interaction of amyloid-beta with ApoE. Subcell Biochem. 2005;38:255-272.
4. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
5. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci. 2000;924:81-90.
6. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
7. Yip AG, McKee AC, Green RC, et al. APOE, vascular pathology, and the AD brain. Neurology. 2005;65:259-265.
8. Li J, Zhang M, Xu ZQ, et al. Vascular risk aggravates the progression of Alzheimer's disease in a Chinese cohort. J Alzheimers Dis. 2010;20:491-500.
9. Viswanathan A, RoccaWA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72:368-374.
10. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184-190.
11. Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007;68:1909-1916.
12. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882-1891.
13. Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76:1485-1491.
14. Carmichael O, Schwarz C, Drucker D, et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer Disease Neuroimaging Initiative. Arch Neurol. 2010;67:1370-1378.
15. Lo RY, Jagust WJ. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012;79:1349-1355.
16. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8:S1-S68.
17. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7:486-488.
18. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version in Clinical Gerontology: A Guide to Assessment and Intervention. New York: The Haworth Press; 1986:165-173.
19. Wechsler D. Manual for the Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1981.
20. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.
21. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
22. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978;14:234-244.
23. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994;25:40-43.
24. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838.
25. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011;70:871-880.
26. Packard CJ, Westendorp RG, Stott DJ, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc. 2007;55:1777-1785.
27. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341: c3666.
28. Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008;65:1202-1208.
29. de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000;47:145-151.
30. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012;69:1621-1627.
31. Unverzagt FW, McClure LA, Wadley VG, et al. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology. 2011;77:1729-1736.
32. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;10:12-20.
33. McCaddon A, Hudson P, Davies G, et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001;12:309-313.
34. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol. 2003;2:425-428.
35. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774-1783.
36. Sakurai H, Hanyu H, Sato T, et al. Vascular risk factors and progression in Alzheimer's disease. Geriatr Gerontol Int. 2011;11:211-214.
37. Altman R, Rutledge JC. The vascular contribution to Alzheimer's disease. Clin Sci (Lond). 2010;119:407-421.
38. Reed B, Villeneuve S, Mack W, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2013;71:195-200.
39. Driscoll I, Espeland MA, Wassertheil-Smoller S, et al. Weight change and cognitive function: findings from the Women's Health Initiative Study of Cognitive Aging. Obesity (Silver Spring). 2011;19:1595-1600.
40. Whitmer RA, Gunderson EP, Quesenberry CP Jr, et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res. 2007;4:103-109.
41. Hughes TF, Borenstein AR, Schofield E, et al. Association between late-life body mass index and dementia: The Kame Project. Neurology. 2009;72:1741-1746.
42. Wysocki M, Luo X, Schmeidler J, et al. Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am J Geriatr Psychiatry. 2012;20:179-187.